Published January 1, 2018
| Version v1
Journal article
Open
Regulatory B cells in myasthenia gravis are differentially affected by therapies
Creators
- 1. Istanbul Univ, Aziz Sancar Inst Expt Med Res DETAE, Dept Neurosci, Istanbul, Turkey
- 2. Sorbonne Univ, INSERM, AIM, Ctr Res Myol,UMRS974, Paris, France
- 3. Pitie Salptriere Hosp, AP HP, Dept Neurol, Paris, France
- 4. Pitie Salptriere Hosp, AP HP, AIM, Neuromuscular Dis Ctr, Paris, France
- 5. Rene Descartes Univ, Cochin Hosp Paris, AP HP, Dept Thorac Surg, Paris, France
Description
We analyzed the number and functionality of regulatory B (Breg) cells in well-defined myasthenia gravis patients. We first showed a decreased number of circulating CD19(+)CD24(++)CD38(++) Breg cells and an altered functionality of Breg cells in untreated myasthenia gravis patients. Next, we demonstrated that the proportion of circulating Breg cells was restored in myasthenia gravis patients after thymectomy, probably as Breg cells could be sequestered in the myasthenia gravis thymus. In contrast, corticosteroid treatments did not restore and decreased even more the proportion of Breg cells in myasthenia gravis patients. These results clearly demonstrated that two distinct immunomodulatory therapies affect differentially Breg cells.
Files
bib-9801ba53-ee26-4b20-bb13-66d094054da4.txt
Files
(265 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:f417ddfa78a7e09018ea2af5489db983
|
265 Bytes | Preview Download |